| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 52 | 2026 | 292 | 10.860 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 43 | 2025 | 210 | 7.800 |
Why?
|
| Connective Tissue Diseases | 18 | 2026 | 75 | 4.300 |
Why?
|
| Autoimmune Diseases | 10 | 2017 | 257 | 2.470 |
Why?
|
| Tomography, X-Ray Computed | 20 | 2024 | 2777 | 2.000 |
Why?
|
| Pulmonary Fibrosis | 10 | 2024 | 152 | 1.960 |
Why?
|
| Pyridones | 6 | 2024 | 68 | 1.840 |
Why?
|
| Alveolitis, Extrinsic Allergic | 7 | 2024 | 43 | 1.780 |
Why?
|
| Indoles | 6 | 2024 | 317 | 1.620 |
Why?
|
| Respiration Disorders | 2 | 2022 | 42 | 1.330 |
Why?
|
| Bronchiectasis | 3 | 2017 | 14 | 1.320 |
Why?
|
| Occupational Exposure | 2 | 2022 | 89 | 1.310 |
Why?
|
| Arthritis, Rheumatoid | 8 | 2026 | 187 | 1.310 |
Why?
|
| Occupational Health | 2 | 2021 | 40 | 1.270 |
Why?
|
| Asthma | 7 | 2025 | 1051 | 1.230 |
Why?
|
| Immunosuppressive Agents | 9 | 2023 | 995 | 1.170 |
Why?
|
| Idiopathic Interstitial Pneumonias | 6 | 2022 | 29 | 1.150 |
Why?
|
| Lung | 20 | 2024 | 1384 | 1.080 |
Why?
|
| Precision Medicine | 2 | 2023 | 454 | 1.040 |
Why?
|
| Humans | 116 | 2026 | 96105 | 1.030 |
Why?
|
| Aged | 55 | 2025 | 20968 | 0.980 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 249 | 0.950 |
Why?
|
| Registries | 8 | 2024 | 986 | 0.930 |
Why?
|
| Respiratory Function Tests | 12 | 2024 | 157 | 0.910 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2025 | 93 | 0.910 |
Why?
|
| Disease Progression | 19 | 2026 | 1562 | 0.900 |
Why?
|
| Male | 74 | 2025 | 45863 | 0.850 |
Why?
|
| Autoimmunity | 6 | 2018 | 192 | 0.840 |
Why?
|
| Sjogren's Syndrome | 3 | 2021 | 34 | 0.830 |
Why?
|
| Middle Aged | 50 | 2025 | 28368 | 0.820 |
Why?
|
| Female | 67 | 2025 | 50028 | 0.810 |
Why?
|
| Retrospective Studies | 30 | 2024 | 10287 | 0.710 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2021 | 6 | 0.710 |
Why?
|
| Proteomics | 6 | 2025 | 268 | 0.700 |
Why?
|
| Survival Analysis | 6 | 2024 | 1546 | 0.690 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 140 | 0.680 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 33 | 0.670 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2026 | 235 | 0.640 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2016 | 19 | 0.640 |
Why?
|
| Hernia, Hiatal | 2 | 2018 | 36 | 0.630 |
Why?
|
| Bronchial Thermoplasty | 1 | 2019 | 6 | 0.630 |
Why?
|
| Pregnancy Complications | 2 | 2025 | 356 | 0.620 |
Why?
|
| Prevalence | 10 | 2024 | 1349 | 0.610 |
Why?
|
| Aspergillus | 2 | 2017 | 9 | 0.580 |
Why?
|
| Hospitalization | 3 | 2021 | 943 | 0.570 |
Why?
|
| Cohort Studies | 17 | 2024 | 3110 | 0.560 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 3 | 2017 | 7 | 0.550 |
Why?
|
| Tacrolimus | 2 | 2017 | 373 | 0.550 |
Why?
|
| Esophagus | 1 | 2018 | 111 | 0.540 |
Why?
|
| Azathioprine | 2 | 2023 | 125 | 0.530 |
Why?
|
| Biological Products | 1 | 2019 | 179 | 0.510 |
Why?
|
| Scleroderma, Systemic | 5 | 2025 | 59 | 0.510 |
Why?
|
| Antifungal Agents | 2 | 2014 | 126 | 0.490 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 611 | 0.480 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 656 | 0.480 |
Why?
|
| Hematologic Neoplasms | 2 | 2017 | 372 | 0.470 |
Why?
|
| Prospective Studies | 12 | 2025 | 4671 | 0.450 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2014 | 4 | 0.450 |
Why?
|
| Telomere | 5 | 2023 | 121 | 0.430 |
Why?
|
| Lung Transplantation | 6 | 2024 | 367 | 0.430 |
Why?
|
| Prognosis | 13 | 2024 | 4028 | 0.430 |
Why?
|
| Diagnosis, Differential | 9 | 2024 | 1619 | 0.430 |
Why?
|
| Referral and Consultation | 3 | 2024 | 386 | 0.430 |
Why?
|
| Biomarkers | 8 | 2025 | 1930 | 0.420 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2020 | 358 | 0.410 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2025 | 294 | 0.410 |
Why?
|
| Vital Capacity | 6 | 2022 | 74 | 0.400 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1805 | 0.390 |
Why?
|
| Muscle, Smooth | 6 | 1996 | 358 | 0.380 |
Why?
|
| Sputum | 1 | 2012 | 36 | 0.380 |
Why?
|
| Adult | 21 | 2023 | 28721 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1096 | 0.370 |
Why?
|
| Biopsy | 4 | 2022 | 1220 | 0.360 |
Why?
|
| Proportional Hazards Models | 8 | 2025 | 901 | 0.350 |
Why?
|
| United States | 12 | 2024 | 7768 | 0.350 |
Why?
|
| Self Care | 1 | 2012 | 170 | 0.350 |
Why?
|
| Bronchodilator Agents | 4 | 2025 | 70 | 0.340 |
Why?
|
| Dermatomyositis | 4 | 2019 | 20 | 0.330 |
Why?
|
| Muscle Contraction | 6 | 1996 | 294 | 0.320 |
Why?
|
| Mucin-5B | 3 | 2019 | 12 | 0.310 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 514 | 0.300 |
Why?
|
| Myositis | 2 | 2020 | 18 | 0.290 |
Why?
|
| Time Factors | 7 | 2024 | 5580 | 0.290 |
Why?
|
| Severity of Illness Index | 8 | 2024 | 1979 | 0.290 |
Why?
|
| Treatment Outcome | 10 | 2024 | 9175 | 0.280 |
Why?
|
| Trachea | 5 | 1996 | 293 | 0.270 |
Why?
|
| Genome-Wide Association Study | 4 | 2023 | 1765 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 396 | 0.260 |
Why?
|
| Quality of Life | 5 | 2025 | 1816 | 0.250 |
Why?
|
| Acetylcysteine | 2 | 2018 | 73 | 0.250 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 424 | 0.250 |
Why?
|
| Fibrosis | 4 | 2022 | 235 | 0.240 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 2039 | 0.230 |
Why?
|
| Environmental Exposure | 2 | 2019 | 357 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 381 | 0.200 |
Why?
|
| Telomerase | 2 | 2020 | 68 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 56 | 0.200 |
Why?
|
| Emphysema | 1 | 2023 | 24 | 0.200 |
Why?
|
| Risk Factors | 7 | 2024 | 5961 | 0.190 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 43 | 0.190 |
Why?
|
| Hypothyroidism | 2 | 2016 | 276 | 0.190 |
Why?
|
| Patient Readmission | 2 | 2024 | 413 | 0.190 |
Why?
|
| Phenotype | 5 | 2020 | 2578 | 0.190 |
Why?
|
| Gastroesophageal Reflux | 3 | 2023 | 121 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2026 | 2480 | 0.180 |
Why?
|
| Mediastinum | 2 | 2019 | 48 | 0.180 |
Why?
|
| Europe | 4 | 2026 | 349 | 0.180 |
Why?
|
| Patient Compliance | 2 | 2020 | 239 | 0.180 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 26 | 0.180 |
Why?
|
| Acetylcholine | 5 | 1996 | 180 | 0.180 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 22 | 0.180 |
Why?
|
| Societies, Medical | 5 | 2026 | 644 | 0.180 |
Why?
|
| Minority Groups | 1 | 2023 | 154 | 0.180 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 20 | 0.180 |
Why?
|
| Polymyositis | 2 | 2013 | 7 | 0.180 |
Why?
|
| Pneumonia | 1 | 2023 | 197 | 0.180 |
Why?
|
| Survival Rate | 5 | 2020 | 1985 | 0.170 |
Why?
|
| Leukotriene Antagonists | 1 | 2001 | 25 | 0.170 |
Why?
|
| Mycophenolic Acid | 2 | 2023 | 86 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 1010 | 0.170 |
Why?
|
| Machine Learning | 1 | 2024 | 348 | 0.170 |
Why?
|
| Blood Proteins | 2 | 2024 | 151 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 84 | 0.160 |
Why?
|
| Hematology | 1 | 2020 | 31 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 137 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 883 | 0.160 |
Why?
|
| Peroxidase | 2 | 2019 | 54 | 0.160 |
Why?
|
| Societies | 1 | 2019 | 16 | 0.160 |
Why?
|
| Fever | 1 | 2020 | 131 | 0.160 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 56 | 0.160 |
Why?
|
| Sexism | 1 | 2020 | 57 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 206 | 0.160 |
Why?
|
| Myeloblastin | 1 | 2019 | 5 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 41 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 294 | 0.150 |
Why?
|
| Aging | 1 | 2024 | 766 | 0.150 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 23 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 7229 | 0.150 |
Why?
|
| Lung Diseases | 1 | 2021 | 290 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 2019 | 106 | 0.140 |
Why?
|
| Antibodies, Antinuclear | 3 | 2018 | 95 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2019 | 565 | 0.140 |
Why?
|
| Eosinophils | 3 | 1993 | 199 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2023 | 591 | 0.140 |
Why?
|
| Comorbidity | 2 | 2024 | 1011 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 2474 | 0.140 |
Why?
|
| Logistic Models | 2 | 2019 | 1268 | 0.140 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 60 | 0.140 |
Why?
|
| Observer Variation | 2 | 2017 | 626 | 0.130 |
Why?
|
| Propensity Score | 1 | 2018 | 180 | 0.130 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 19 | 0.130 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 220 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.130 |
Why?
|
| Chicago | 2 | 2024 | 1506 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2017 | 983 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 241 | 0.130 |
Why?
|
| Cause of Death | 1 | 2018 | 278 | 0.130 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 39 | 0.130 |
Why?
|
| Prednisone | 1 | 2017 | 258 | 0.130 |
Why?
|
| Radiography | 2 | 2016 | 826 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 2463 | 0.130 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 25 | 0.130 |
Why?
|
| Clinical Studies as Topic | 1 | 2016 | 4 | 0.130 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 6 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 117 | 0.120 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 68 | 0.120 |
Why?
|
| Granuloma | 1 | 2016 | 65 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2017 | 236 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 155 | 0.120 |
Why?
|
| Total Lung Capacity | 1 | 2016 | 11 | 0.120 |
Why?
|
| Polylysine | 1 | 1996 | 34 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 123 | 0.120 |
Why?
|
| Leukocytes | 3 | 2023 | 218 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 151 | 0.120 |
Why?
|
| Phospholipases A | 2 | 1993 | 45 | 0.120 |
Why?
|
| Glucocorticoids | 2 | 2010 | 369 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 397 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2020 | 441 | 0.120 |
Why?
|
| Transcriptome | 1 | 2021 | 769 | 0.120 |
Why?
|
| Ribonucleases | 1 | 1996 | 97 | 0.120 |
Why?
|
| Physician's Role | 1 | 2017 | 186 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2018 | 683 | 0.110 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 341 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 1973 | 0.110 |
Why?
|
| Pregnancy | 2 | 2025 | 3240 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2017 | 489 | 0.110 |
Why?
|
| Antigens | 1 | 2016 | 231 | 0.110 |
Why?
|
| Radiography, Thoracic | 2 | 2018 | 334 | 0.110 |
Why?
|
| Pulmonary Medicine | 1 | 2015 | 51 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1021 | 0.110 |
Why?
|
| Guinea Pigs | 5 | 1996 | 172 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 273 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 378 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1179 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2880 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 205 | 0.100 |
Why?
|
| Macrolides | 1 | 2013 | 31 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 813 | 0.100 |
Why?
|
| Antifibrinolytic Agents | 1 | 2014 | 44 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 484 | 0.100 |
Why?
|
| Adalimumab | 1 | 2014 | 92 | 0.100 |
Why?
|
| Phenylpropionates | 1 | 2013 | 7 | 0.100 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2013 | 9 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 456 | 0.100 |
Why?
|
| Pyridazines | 1 | 2013 | 22 | 0.100 |
Why?
|
| Bronchi | 2 | 2013 | 234 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2013 | 75 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2013 | 94 | 0.100 |
Why?
|
| Airway Management | 1 | 2013 | 48 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1176 | 0.090 |
Why?
|
| Peptides | 1 | 1996 | 671 | 0.090 |
Why?
|
| Rheumatology | 2 | 2025 | 39 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1670 | 0.090 |
Why?
|
| Canada | 2 | 2023 | 215 | 0.090 |
Why?
|
| Serotonin | 1 | 1993 | 219 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 1172 | 0.090 |
Why?
|
| Child | 1 | 2023 | 7625 | 0.090 |
Why?
|
| Palliative Care | 1 | 2013 | 273 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 202 | 0.080 |
Why?
|
| Voriconazole | 1 | 2010 | 19 | 0.080 |
Why?
|
| In Vitro Techniques | 5 | 1996 | 1010 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2015 | 984 | 0.080 |
Why?
|
| Immunoglobulin E | 1 | 2010 | 152 | 0.080 |
Why?
|
| Young Adult | 3 | 2017 | 7025 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1535 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1957 | 0.080 |
Why?
|
| Triazoles | 1 | 2010 | 110 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 151 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 220 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1133 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2860 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 1429 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 847 | 0.070 |
Why?
|
| Neoplasms | 1 | 2023 | 3248 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2010 | 386 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 810 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2011 | 306 | 0.060 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 9 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 943 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2006 | 30 | 0.060 |
Why?
|
| Nitriles | 1 | 2006 | 157 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2591 | 0.060 |
Why?
|
| California | 1 | 2025 | 161 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2025 | 203 | 0.060 |
Why?
|
| Life Style | 1 | 2025 | 186 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 22 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 27 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2025 | 273 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2023 | 98 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2014 | 1791 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 31 | 0.050 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.050 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2003 | 9 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2026 | 458 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2025 | 228 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 2022 | 24 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 150 | 0.050 |
Why?
|
| Antacids | 1 | 2022 | 4 | 0.050 |
Why?
|
| North America | 1 | 2023 | 199 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2019 | 1423 | 0.050 |
Why?
|
| Cough | 1 | 2022 | 57 | 0.050 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2021 | 27 | 0.040 |
Why?
|
| Pulmonologists | 1 | 2021 | 7 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 19 | 0.040 |
Why?
|
| Radiologists | 1 | 2021 | 54 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2001 | 48 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 370 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 137 | 0.040 |
Why?
|
| Biology | 1 | 2020 | 52 | 0.040 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2020 | 11 | 0.040 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 21 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2020 | 7 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 17 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 120 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 58 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 66 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 3 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 9 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 366 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 14 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 4 | 0.040 |
Why?
|
| Animals | 8 | 2017 | 28891 | 0.040 |
Why?
|
| Vasculitis | 1 | 2019 | 40 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 64 | 0.040 |
Why?
|
| Ireland | 1 | 2019 | 12 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 68 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 90 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 142 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 483 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 217 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 192 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 61 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 361 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 412 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 42 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2020 | 3581 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 103 | 0.030 |
Why?
|
| Microscopic Angioscopy | 1 | 2016 | 1 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 297 | 0.030 |
Why?
|
| Cytochalasin B | 2 | 1993 | 19 | 0.030 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 2 | 1993 | 39 | 0.030 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 1993 | 36 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 393 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 453 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2017 | 151 | 0.030 |
Why?
|
| Eosinophil Granule Proteins | 1 | 1996 | 20 | 0.030 |
Why?
|
| Cations | 1 | 1996 | 32 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 40 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 996 | 0.030 |
Why?
|
| Atropine | 1 | 1996 | 61 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 1993 | 44 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 18 | 0.030 |
Why?
|
| Acetophenones | 2 | 1993 | 27 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 910 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1320 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 2015 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1876 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 51 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 540 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1063 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 605 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 212 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2939 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 599 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 668 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 360 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 281 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 531 | 0.030 |
Why?
|
| Kinetics | 2 | 1993 | 1562 | 0.030 |
Why?
|
| Blood Cells | 1 | 1993 | 34 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1993 | 20 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 701 | 0.030 |
Why?
|
| Phenyl Ethers | 1 | 1993 | 13 | 0.030 |
Why?
|
| Acetamides | 1 | 1993 | 27 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 133 | 0.020 |
Why?
|
| Fetal Blood | 1 | 1993 | 96 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1993 | 91 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2013 | 98 | 0.020 |
Why?
|
| Advance Care Planning | 1 | 2013 | 44 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 688 | 0.020 |
Why?
|
| 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine | 1 | 1992 | 4 | 0.020 |
Why?
|
| Eicosanoids | 1 | 1992 | 17 | 0.020 |
Why?
|
| Receptors, Muscarinic | 1 | 1992 | 48 | 0.020 |
Why?
|
| Epithelium | 1 | 1993 | 322 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1992 | 77 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 2161 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 295 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1993 | 397 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 45 | 0.020 |
Why?
|
| Terminal Care | 1 | 2013 | 146 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1991 | 53 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 1991 | 92 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 509 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2534 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3489 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 857 | 0.020 |
Why?
|
| Body Water | 1 | 1989 | 35 | 0.020 |
Why?
|
| Body Temperature Regulation | 1 | 1989 | 60 | 0.020 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 1989 | 49 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 4374 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 491 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2061 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2494 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 694 | 0.020 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2006 | 10 | 0.020 |
Why?
|
| Carboxylic Acids | 1 | 2006 | 17 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2006 | 137 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 12537 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 3927 | 0.010 |
Why?
|
| Leukotriene C4 | 1 | 1993 | 21 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 1993 | 67 | 0.010 |
Why?
|
| Quinacrine | 1 | 1993 | 14 | 0.010 |
Why?
|
| Eosinophil Peroxidase | 1 | 1993 | 14 | 0.010 |
Why?
|
| SRS-A | 1 | 1993 | 27 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1993 | 113 | 0.010 |
Why?
|
| Peroxidases | 1 | 1993 | 34 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1993 | 65 | 0.010 |
Why?
|
| Superoxides | 1 | 1993 | 76 | 0.010 |
Why?
|
| Cell Separation | 1 | 1993 | 205 | 0.010 |
Why?
|
| Tachyphylaxis | 1 | 1991 | 14 | 0.010 |
Why?
|
| Pyridinium Compounds | 1 | 1991 | 10 | 0.010 |
Why?
|
| Blood | 1 | 1991 | 69 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 311 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1991 | 197 | 0.010 |
Why?
|
| Homeostasis | 1 | 1993 | 467 | 0.010 |
Why?
|
| Perfusion | 1 | 1991 | 266 | 0.000 |
Why?
|
| Respiratory System | 1 | 1989 | 121 | 0.000 |
Why?
|
| Dogs | 1 | 1989 | 719 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 4155 | 0.000 |
Why?
|